Overview

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Status:
Terminated

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well octreotide works in reducing diarrhea in patients receiving cabazitaxel and prednisone for hormone-resistant prostate cancer (HRPC) previously treated with docetaxel. Octreotide may prevent diarrhea by blocking the secretion of several hormones in patients receiving chemotherapy for prostate cancer

Phase:

Phase 2

Details

Lead Sponsor:

University of Southern California

Collaborators:

National Cancer Institute (NCI)
Sanofi

Treatments:

Docetaxel
Octreotide
Prednisone